| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 5697665 | Cancer Treatment Reviews | 2017 | 11 Pages | 
Abstract
												NTx in PDAC seems to exert its beneficial effect in borderline or locally advanced PDAC over genuine tumor downstaging. Thus, although at least 40% of all NTx treated patients remain unresectable even with modern NTx regimes, neoadjuvantly treated PDAC showed not only increasing resectability rates especially after FOLFIRINOX, but even reach a lower tumor stage than primarily resected PDAC.
											Keywords
												
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Oncology
												
											Authors
												Stephan Schorn, Ihsan Ekin Demir, Carmen Mota Reyes, Cemil Saricaoglu, Nicole Samm, Rebekka Schirren, Elke Tieftrunk, Daniel Hartmann, Helmut Friess, Güralp Onur Ceyhan, 
											